ACIU News & Events

AC Immune (ACIU) announced an agreement with Eli Lilly (LLY) to amend their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. The amendment continues the research and collaboration to cover development of new lead Tau Morphomer candidates and potential back-up compounds. Under this amendment, AC Immune will receive a CHF 10M upfront payment and a subsequent milestone payment with Phase 1 dosing, in addition to milestones announced in a prior amendment. AC Immune is eligible for further development, regulatory and commercial milestones of over CHF1.7B, plus tiered percentage royalty payments in the low double digits, as previously disclosed.

AC Immune announced the presentation of Phase 1 data including the first in vivo images of TDP-43 pathology in the human brain, detected using its positron emission tomography - PET - tracer ACI-19626, at the International Conference on Alzheimer's and Parkinson's Disease. Initial data from the Phase 1 trial support ACI-19626's potential to detect pathological TDP-43 in the brains of patients with TDP-43 proteinopathies, enabling a precision medicine approach to multiple neurodegenerative diseases. Specifically, PET scans with ACI-19626 showed that tracer uptake was significantly higher in key regions of the brain in patients with frontotemporal dementia due to mutated C9orf72 than in the brains of healthy subjects. ACI-19626 showed good safety and tolerability, a dosimetry profile within accepted limits, and rapid brain uptake and washout, indicating a PK profile suitable for human brain imaging and potentially pharmacodynamic analysis of therapeutics targeting TDP-43 pathology. This potentially enables precision medicine across multiple neurodegenerative diseases.

Reports FY25 revenue CHF 3.753M vs CHF 27.309M last year. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "We made significant progress towards delivering precision prevention of neurodegenerative diseases in 2025, exemplified by the exceptional interim data from the VacSYn trial of ACI-7104, our wholly-owned active immunotherapy targeting alpha-synuclein. Evidence that ACI-7104 appears to slow the rate of progression in early Parkinson's disease (PD) further demonstrates the potential for active immunotherapies as disease-modifying treatments with the potential to slow or prevent neuronal damage."